What Dose of Zepbound Is Most Effective? The SURMOUNT-1 Evidence

If you want the single number: in SURMOUNT-1, the pivotal obesity trial, 15 mg produced the largest average weight reduction of the three tirzepatide doses tested (Jastreboff 2022^[1]). But “largest average” is not the same as “the right dose for you,” and the FDA label is deliberately not prescriptive about it: for weight reduction it names 5 mg, 10 mg or 15 mg once weekly as maintenance dosages and tells prescribers to “consider treatment response and tolerability when selecting the maintenance dosage”^[4]. That means a person losing well at 5 mg with no nausea is on a labeled maintenance dose, not an incomplete one. Here is what each dose actually delivered, why the gap between 10 and 15 mg is narrower than most people expect, and how to think about stopping where you are.

The honest summary

• 15 mg gave the biggest average loss in the pivotal trial. SURMOUNT-1 randomised adults with obesity or overweight to tirzepatide 5, 10 or 15 mg weekly against placebo over 72 weeks, and weight reduction increased across the three doses (Jastreboff 2022^[1]).
• But all three are labeled maintenance doses. Verbatim: “Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly”^[4]. Stopping at 5 mg or 10 mg is on-label, not under-treatment.
• The label tells prescribers to weigh two things. “Consider treatment response and tolerability when selecting the maintenance dosage”^[4] — so if you are responding well and the higher dose costs you side effects, that trade-off is exactly what the label contemplates.
• Escalation exists for tolerability, not effect. Start at 2.5 mg for 4 weeks, then increase in 2.5 mg increments after at least 4 weeks^[4]. The 2.5 mg starting dose is explicitly not a maintenance dose.
• Early response predicts later response. A SURMOUNT-1 post hoc analysis found weight reduction over time tracked with how much people lost early (Ard 2025^[3]) — useful for judging whether your current dose is working before reaching for the next one.
• 15 mg is the ceiling. “The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly”^[4]. There is no sanctioned dose above it.

What SURMOUNT-1 actually tested

SURMOUNT-1 (Jastreboff 2022^[1], New England Journal of Medicine) is the trial the Zepbound obesity approval rests on. Adults with obesity, or overweight with at least one weight-related complication and without diabetes, were randomised to once-weekly tirzepatide at 5 mg, 10 mg or 15 mg, or to placebo, and followed for 72 weeks. The three-arm design is what makes it useful here: it is a genuine dose-comparison rather than a single dose against placebo, so it can speak to whether more milligrams buy more weight loss.

The direction of the answer is not in doubt — mean weight reduction rose across the dose arms. What gets lost in the headline is the shape of that increase. The step from placebo to 5 mg is enormous. The step from 5 mg to 10 mg is meaningful. The step from 10 mg to 15 mg is the smallest of the three. That matters because the side-effect burden does not flatten in the same way, which is the entire reason the label offers three maintenance options instead of naming one.

The label: three maintenance doses, not one target

Recommended Maintenance and Maximum Dosage — Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. … Consider treatment response and tolerability when selecting the maintenance dosage. … Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly.

— ZEPBOUND prescribing information, Dosage and Administration (DailyMed)[[cite:4]]

Note the sleep-apnea asymmetry: for obstructive sleep apnea the label restricts maintenance to 10 mg or 15 mg^[4], not 5 mg. So the same drug has a higher floor when the target is OSA than when it is weight reduction — a detail worth raising if you are being treated for both.

How to tell whether your current dose is working

Ard 2025^[3] is a post hoc analysis of SURMOUNT-1 that grouped participants by their early weight-loss response and followed the trajectories out. The useful takeaway is that early response carried information about later response — people who were losing meaningfully in the first months tended to keep going. That gives you something more concrete than a feeling when deciding whether to escalate: if your current dose is producing steady loss, the case for climbing is weaker than if you have genuinely stalled.

A plateau is not automatically a dose problem either. Adherence, protein and resistance training, sleep, other medications and simple measurement noise all produce flat weeks. Our plateau guide works through the alternatives before milligrams. And if the reason you are hesitating to go up is side effects rather than results, the tolerability conversation is the one to have — the label anticipates it directly.

Longer-term data

Jastreboff 2025^[2] extended the SURMOUNT-1 population, reporting on tirzepatide for obesity treatment and diabetes prevention over a substantially longer horizon in the New England Journal of Medicine. For a dose question the relevance is that the effect was durable with continued treatment rather than a short-lived early drop — which reframes the decision. If you are choosing a dose you may hold for years, tolerability at that dose stops being a minor consideration and becomes most of the argument.

Practical framing

1. Do not treat 15 mg as the goal by default. It produced the largest average effect, but 5 mg and 10 mg are labeled maintenance doses, and the label picks between them on response and tolerability^[4].
2. Judge your own response with numbers. Early response carried predictive information in SURMOUNT-1's post hoc analysis^[3]; a vague sense of progress does not.
3. Escalate for stalled results, not on schedule. The 2.5 mg increments exist to manage tolerability, not because a calendar says so.
4. Rule out non-dose causes of a plateau first — see the plateau guide.
5. Know the ceiling. 15 mg weekly is the maximum for every indication^[4]. Anything above it has no label behind it.
6. If you are treated for sleep apnea, the floor is higher — 10 mg or 15 mg, not 5 mg^[4].

The bottom line

The population answer is 15 mg: it produced the largest mean weight reduction among the doses tested in SURMOUNT-1^[1]. The individual answer is whichever labeled maintenance dose — 5, 10 or 15 mg — gives you a response you are satisfied with at a side-effect cost you can sustain, which is precisely the trade-off the FDA label instructs prescribers to make^[4]. Given the evidence that the effect persists with continued treatment^[2], the dose you can actually stay on matters more than the dose with the best trial average.